莱美药业2025年净利预亏1.2亿元至1.35亿元

Core Viewpoint - Laimei Pharmaceutical (300006) forecasts a net profit loss of between 120 million to 135 million yuan for 2025, compared to a loss of 87.8044 million yuan in the same period last year [1] Group 1: Financial Performance - The company's revenue is expected to slightly decrease year-on-year due to a decline in sales volume and prices of certain products [1] - The company plans to continue its R&D investments to enrich its product pipeline, which will impact operating profits [1] Group 2: Asset and Investment Impacts - Some intangible assets are showing signs of impairment due to centralized procurement policies, with an estimated impairment provision of about 60 million yuan [1] - The company has recognized an investment loss of approximately 23 million yuan due to increased R&D expenditures and fair value changes in certain joint ventures [1]